Skip to content
DataLookout
Menu

RAPIDNCT05979545

EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics

StatusRecruiting
PhasePhase 4
Primary completion (estimated)

At risk: Primary completion moved 12 months later, primary endpoint(s) modified, and 1 more.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Oct 31, 2026 to Oct 31, 2027 Show 7 more changesShow less
    • Primary endpoint(s) modified
    • Eligibility criteria expanded, about 95 words
    • Enrollment reduced: 1900 → 1526 participants
    • Trial sites expanded: 4 → 21 locations
    • Study completion pushed from Dec 31, 2026 to Dec 31, 2027
    • Secondary endpoints: 5 to 21
    • Study description expanded, about 64 words
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 1, 2023 to Dec 12, 2023
    • Secondary endpoints revised (5)
    • Study title shortened, about 25 words
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Composite of All-Cause Mortality or Absence of SOFA Score Improvement at Day 14
Timeframe: Day 14 following index culture.

Secondary (21)

Clinical Response at Day 7 and Day 14
All-Cause Mortality at Day 14, Day 28 and Day 60
Functional Status and Health-Related Quality of Life
Desirability of Outcome Ranking (DOOR) at Day 28
Implementation Costs and Health Economic Outcomes
Show 16 moreShow less
Days Alive and Out of Hospital Within 60 Days
Length of Intensive Care Unit Stay
Length of Hospital Stay
Duration of Mechanical Ventilation
Type of Accommodation Upon Hospital Discharge
Persistence of Bacteraemia at Day 4
Microbiological Growth in Respiratory Cultures at Day 7
Development of Resistance to Meropenem or Ceftazidime-Avibactam
Incidence of Acute Kidney Injury
Incidence of Clostridioides difficile Diarrhoea
Time From Index Culture to Active Antibiotic Therapy
Number of Days on Antibiotic Treatment Within 28 Days
Antibiotic Treatment Modification Following Microbiological Diagnosis
Time to Detection of Carbapenemase Production or Carbapenem Resistance
Time to Detection of Third-Generation Cephalosporin Resistance
Time to Identification of Other Multidrug-Resistant Gram-Negative Pathogens

Arms and interventions

InterventionActive comparator

Rapid microbiological diagnostics using the BioFire BCID2 Panel for bloodstream infections or BioFire FilmArray Pneumonia/Pneumonia Plus Panel for respiratory infections, combined with locally adapted antimicrobial stewardship and early targeted antibiotic therapy. Samples from patients randomised to the intervention arm will undergo the BioFire FilmArray systems. Patients will be then administered with the study drug, ceftazidime-avibactam when Pseudomonas aeruginosa or carbapenemase producing Enterobacterales detected. Appropriate antibiotic must be administered according to predefined antibiotic stewardship guidelines within 24 hours of the Gram stain being performed on the index specimen.

ControlNo intervention

Standard-of-care microbiological diagnostics and antibiotic treatment according to local clinical practice and treating physician discretion. Patients randomised to the control arm, will have samples analysed by clinical microbiology laboratories using standard of care diagnostics. Antibiotics treatment will be administered as per usual institutional practice from hospital supplies.

Diagnostic tests: Rapid Diagnostics

Sites

21 sites in 7 countries

Malaysia 5, South Korea 4, Taiwan 4, Thailand 4, Singapore 2, India 1, Turkey (Türkiye) 1